Since 2011, the United Kingdom has set aside £200 million per year through the Cancer Drug Fund (CDF) to pay for oncology treatments not reviewed or approved by NICE. The CDF reviews pivotal trial data and scores drugs on disease-free/progression-free survival (PFS), overall survival (OS), quality of life (QoL), safety, unmet need, and strength of evidence. The score determines if the drug will be included on the CDF priority list. Due to the rising costs of cancer treatment and overspending in the CDF budget, the CDF added cost as a parameter in November 2014. This necessitated a re-review of all drugs on the priority list and prompted stakeholders to question whether cost would become the most influential parameter in the CDF decisionmaking process. This analysis attempts to determine if the importance of OS and PFS has diminished now that cost has been added to the evaluation. As manufacturers develop novel life-saving therapies, is cost more important than OS and PFS in the CDF evaluation of drugs?
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METHODS
TThe data include the 82 CDF decision summaries published from April 2013 to July 2014 (pre-cost data set) and 56 CDF decision summaries published in January 2015 (post-cost data set). The data scores for each parameter were included: PFS, OS, QoL, safety, unmet need, strength of evidence, and median cost (in the post-cost data set). Median cost was calculated by multiplying the cost of a treatment by the median duration of treatment. The CDF decision was classified as positive (recommended listing on the CDF priority list) or negative (did not recommend listing on the CDF priority list). Deferred decisions and drugs not scored (situations where a lack of data prevented the CDF from making a final decision) were excluded (n=27).
Two independent probit logistical regression models were used to estimate the probability of a positive decision based on the scores for the individual parameters (e.g., OS, PFS) for both pre-and post-cost data sets. Both models excluded parameters with collinearity and parameters that perfectly predicted positive decisions (due to small sample size). The predictive powers of OS and PFS were compared to each other in the pre-and post-cost models.
RESULTS
In the pre-cost model, OS was the only strong predictor of a positive reimbursement decision. An increase in OS was related to a higher probability of achieving a positive reimbursement decision (p=.031). If OS was less than two months, the probability of a positive decision was 41%, but the probability of a positive decision increased to 95% for a 4-5 month improvement in OS. In the post-cost model, PFS, OS, and median cost were strong predictors of a positive CDF decision (p=.07, p=.044, and p=.026, respectively). When OS was less than 2 months, the probability of a positive CDF decision was 35%. As OS increased to 4-5 months, the probability of a positive decision increased to 78%. PFS was also an important predictor of a positive decision in the postcost model. When PFS was less than 2 months, the probability of a positive decision was just 29%. As PFS increased to 4-5 months, the probability of a positive reimbursement decision increased to 48%.
CONCLUSIONS
OS was a strong predictor of a positive reimbursement decision in both the pre-and post-cost models. PFS emerged as a strong predictor of a positive reimbursement decision in the post-cost model. When we compare the importance of OS and PFS to a positive decision, a higher score in OS is a stronger predictor. Even when costs are taken into account, a drug's performance on OS and PFS remain important influences on a positive decision. In the new CDF process, cost is important, but it is not the only influential parameter leading to a positive reimbursement decision. 
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